| |
Music device doesn't drop diabetics' blood pressure Wednesday, Jun 12, 2013 12:27 PM PDT By Andrew M. Seaman NEW YORK (Reuters Health) - A device that plays a melody in an attempt to slow people's breathing didn't lower the blood pressure of people with diabetes, according to a new study. "Given the results and the studies available, you can conclude that there is not enough evidence to use this device," said Dr. Gijs Landman, the study's lead author from the Isala Clinics in The Netherlands. ... Full Story | Top |
Irish PM says received letters in blood over planned abortion law Wednesday, Jun 12, 2013 10:39 AM PDT | Top |
AIDS drugs halve HIV risk for intravenous drug users in study Wednesday, Jun 12, 2013 10:27 AM PDT | Top |
Australian woman attempts record swim from Cuba to U.S. Wednesday, Jun 12, 2013 10:18 AM PDT | Top |
Girl who needed judge's order to be on transplant list to get new lung Wednesday, Jun 12, 2013 09:30 AM PDT (Reuters) - A lung donor has been found for a 10-year-old girl with cystic fibrosis who only became eligible for an adult organ transplant because of a judge's order, her mother said on Wednesday. Sarah Murnaghan, who had been kept off an adult organ transplant list due to an age restriction prior to the judge's ruling, was being prepped for surgery in an operating room at Children's Hospital of Philadelphia, her mother, Janet Murnaghan, wrote on Facebook. "Sarah got THE CALL," she wrote. "Please pray for Sarah's donor, her HERO, who has given her the gift of life. ... Full Story | Top |
Amgen says drug slowed ovarian cancer in trial Wednesday, Jun 12, 2013 09:26 AM PDT (Reuters) - Amgen Inc's trebananib drug for ovarian cancer extended the length of time that patients lived without the disease getting worse by about two months, meeting the main goal of a late-stage clinical trial, the company said on Wednesday. The trial is the first of three pivotal-stage studies of the experimental drug, and analysts said U.S. regulators will likely need to see evidence that trebananib extends overall patient survival before considering the drug for marketing approval. Amgen said median progression free survival (PFS) in the trial was 7. ... Full Story | Top |
Soda ban would target heavy youth, not poor: study Wednesday, Jun 12, 2013 09:06 AM PDT By Genevra Pittman NEW YORK (Reuters Health) - A cap on soda size - such as the one New York City regulators are trying to pass - would have the biggest impact on overweight kids and young adults, a new study suggests. When limited to drinks sold in restaurants and event spaces, researchers found the policy is not likely to disproportionately affect poorer patrons, which has been an argument against the measure. "We want to target the right people, and want it so it's not unfairly targeted at, for example, resource-poor communities," said Dr. Y. Claire Wang, who worked on the study. ... Full Story | Top |
Cleveland man pleads not guilty to murder, serial rape Wednesday, Jun 12, 2013 08:59 AM PDT | Top |
Teva, Sun Pharma to pay $2.15 billion to settle Pfizer patent suit Wednesday, Jun 12, 2013 08:43 AM PDT | Top |
Mandela responding better to treatment: South Africa's Zuma Wednesday, Jun 12, 2013 08:28 AM PDT | Top |
Economic, social pressures behind Kuwait crackdown on foreign workers Wednesday, Jun 12, 2013 07:15 AM PDT | Top |
Britain to regulate e-cigarettes as medicine from 2016 Wednesday, Jun 12, 2013 07:08 AM PDT By Ben Hirschler LONDON (Reuters) - Britain is to regulate electronic cigarettes as non-prescription medicines from 2016 in an attempt to improve quality, though the country's drugs watchdog said they would still be sold in convenience stores. Healthcare authorities around the world are grappling with how to deal with the battery-driven devices, which allow users to inhale nicotine-laced vapour and are increasingly popular as an apparently less harmful alternative to smoking. ... Full Story | Top |
British healthcare body recommends Thrombogenics drug Tuesday, Jun 11, 2013 10:19 PM PDT BRUSSELS (Reuters) - Belgian biotech group Thrombogenics said on Wednesday that it received a positive initial recommendation from British healthcare body NICE that its eye drug Jetrea qualify for reimbursement to patients. The company said a final decision is expected in the third quarter of this year. (Reporting by Robert-Jan Bartunek; Editing by Edwina Gibbs) Full Story | Top |
Restrictive drug laws censor science, researchers say Tuesday, Jun 11, 2013 09:18 PM PDT | Top |
GSK offers discount to win UK green light for platelet drug Tuesday, Jun 11, 2013 05:06 PM PDT | Top |
|
No comments:
Post a Comment